The company's primary focus is to advance global development of vebreltinib for treatment of patients with c-MET alterations, with plans to submit an IND Application for accelerated approval in NSCLC in the first half of 2027. Beyond its lead c-Met inhibitor, the pipeline includes uproleselan for acute myeloid leukemia and three new immuno-oncology candidates (APL-501, APL-502, APL-801) with mono-specific and bi-specific antibodies.
Cyborg Score Rationale
The company received a Nasdaq noncompliance notice in June 2026 regarding minimum market value requirements, and faces cash constraints evidenced by a $2.0 million bridge loan from its CEO in March 2026 to support clinical development programs and operations. With market cap of $32.2M as of May 2026 and trailing twelve-month revenue of $8.5M, the company remains micro-capitalized and pre-commercial.
Top Insights
Lead program vebreltinib has dosed over 600 patients and 170 healthy volunteers in clinical trials, demonstrating clinical progress and potential de-risking ahead of 2027 IND submission
CEO bridge financing of $2.0M in March 2026 signals near-term cash constraints despite clinical advancement
Nasdaq deficiency notice in June 2026 creates regulatory delisting risk requiring equity raise or clinical/financial milestone achievement
Diversified pipeline spanning c-Met inhibition, AML, and immuno-oncology reduces single-asset risk and addresses combined $11B+ market opportunity
Named Competitors
c-Met inhibitors — Large pharma with c-Met programs in oncology
Immuno-oncology antibodies — Leading oncology and immuno-oncology innovator
Early-stage AML therapies — Clinical-stage biotech in hematologic malignancies
Oncology programs — Immuno-oncology company with antibody programs
Recent Developments
(June 2026) Received Nasdaq deficiency notice regarding minimum market value requirement
(April 2026) Announced full year 2025 financial results; CEO provided $2.0M bridge financing for working capital
(December 2024) Uproleselan Phase 3 bridge trial showed positive results in relapsed/refractory AML in China
Open the full interactive Apollomics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.